New CAR-T therapy targets tough blood cancers in early trial
NCT ID NCT07345728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called BAFFR CAR-T for people with B-cell blood cancers that have returned or not responded to standard therapy. The therapy uses a patient's own immune cells, modified to attack cancer cells. The goal is to see if it is safe and helps control the disease. About 28 adults aged 18-85 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, 448000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- New cell therapy takes aim at Hard-to-Treat blood cancers
- Engineered immune cells take aim at tough childhood cancers
- Experimental Dual-Target CAR-T therapy enters human testing for tough blood cancers
- Experimental 'Off-the-Shelf' CAR-T therapy takes on tough lymphoma
- Promising CAR-T trial for blood cancer withdrawn before starting